ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.40 | -$0.03 | Beat |
| May 18, 2026 | – | -$0.06 | |
| Mar 3, 2026 | – | -$0.12 | |
| Oct 31, 2025 | -$0.40 | -$0.05 | Beat |
| Aug 13, 2025 | -$0.60 | -$0.13 | Beat |
| Apr 30, 2025 | -$0.50 | $0.04 | Beat |